Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FER | P16591 | 1/20 | 0.53 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indirubin SCHEMBL31032717 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL30215500 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL20535353 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL29361016 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL27678 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL6809175 | 1.00 | MAOA (0.64) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL3857676 | 0.98 | MAOA (0.62) | MAOAMAOBLRRK2PDGFRAFER | |
| Indirubin SCHEMBL21067723 | 0.93 | MAOA (0.56) | MAOAMAOBLRRK2PDGFRAFER | |
| SCHEMBL22300581 | 0.87 | MAOA (0.50) | MAOAMAOBLRRK2PDGFRAFER | |
| SCHEMBL21440382 | 0.86 | MAOA (0.49) | MAOAMAOBLRRK2PDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674839-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | CK Regeon Inc. (KR) | 2026-01-07 | — | — | EP | disclosed |
| US-12516022-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2024181799-A1 | NOVEL INDOLINE DERIVATIVE AND USE THEREOF | 주식회사 씨케이리제온 | 2024-09-06 | — | — | WO | disclosed |
| EP-4412991-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118317948-A | Derivatives of aromatic hydrocarbon receptor agonists | 阿佐拉治疗股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | Pelemed Co., Ltd. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20090037136-A1 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-05 | — | — | US | disclosed |
| US-20090037136-A1 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-05 | — | — | US | disclosed |
| US-20080227640-A1 | Plant Growth Regulation | BAYER CROPSCIENCE GMBH (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227640-A1 | Plant Growth Regulation | BAYER CROPSCIENCE GMBH (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20070276025-A1 | Indirubin-Type Compounds, Compositions, and Methods for Their Use | MEIJER LAURENT | 2007-11-29 | — | — | US | disclosed |
| US-20070276025-A1 | Indirubin-Type Compounds, Compositions, and Methods for Their Use | MEIJER LAURENT | 2007-11-29 | — | — | US | disclosed |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | ANYGEN CO., LTD. (KR) | 2007-07-05 | — | — | US | disclosed |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | ANYGEN CO., LTD. (KR) | 2007-07-05 | — | — | US | disclosed |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | LIU YAGUANG (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | LIU YAGUANG (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | MAOA 414/4885MAOB 318/4885LRRK2 872/4885 |
| US-20080227640-A1 | Plant Growth Regulation | ING2, NANS, CCNH | MAOA 2377/4885MAOB 1893/4885LRRK2 1957/4885 |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | MATR3, HPN, HAMP | MAOA 1249/4885MAOB 1993/4885LRRK2 3531/4885 |
| US-20070276025-A1 | Indirubin-Type Compounds, Compositions, and Methods for Their Use | CDK3, GSK3B, CDK7 | MAOA 1165/4885MAOB 873/4885LRRK2 1110/4885 |
| US-20240010635-A1 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | FLT3, RET, FER | MAOA 2977/4885MAOB 1138/4885LRRK2 181/4885 |
| US-20240182416-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | MAOA 414/4885MAOB 318/4885LRRK2 872/4885 |
| US-20070155816-A1 | CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime | CDK7, CDKL5, CDK3 | MAOA 2666/4885MAOB 1645/4885LRRK2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.